BIIB · Biogen Inc.
$216.032026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$222
+2.8% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($222 · $223) Analysts Range ($185 · $260) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $9.8B | — | 21.3% | 11.8% | $1.9B | −$7.3B | −$5.4B | 5.1% | — | 6.1% | $30.4B | $7.82 | — |
| 2024.Q4 | $9.8B | 0.0% | 21.3% | 14.4% | $1.8B | −$748MM | $1.0B | 5.3% | — | 5.9% | $30.4B | $7.82 | — |
| 2025.Q1 | $9.7B | -1.6% | 25.7% | 15.6% | $2.1B | −$757MM | $1.3B | 5.2% | — | 7.0% | $29.7B | $11.00 | — |
| 2025.Q4 | $9.7B | 0.0% | 25.7% | 7.7% | $2.3B | −$189MM | $2.1B | 5.0% | — | 7.7% | $30.1B | $11.00 | — |
| 2026.Q1 | $9.9B | 1.9% | 15.6% | 6.5% | $1.4B | $105MM | $1.5B | 5.0% | — | 5.0% | $27.7B | $9.25 | 20.8 |
| italics below = DCF projection · 10yr Rev CAGR: 3.1% |
| 2027.Q1 | $10.0B | +1.4% | 19.1% | 7.9% | $1.8B | −$380MM | $1.4B | 6.1% | $1.3B | 6.3% | $28.1B | $11.85 | 18.2 |
| 2028.Q1 | $10.2B | +2.1% | 20.3% | 9.2% | $1.9B | −$604MM | $1.3B | 6.3% | $1.1B | 6.6% | $28.7B | $12.67 | 17.1 |
| 2029.Q1 | $10.4B | +2.5% | 25.3% | 10.6% | $2.4B | −$737MM | $1.6B | 6.6% | $1.4B | 8.1% | $29.4B | $15.91 | 13.6 |
| 2030.Q1 | $10.8B | +2.9% | 26.8% | 11.9% | $2.5B | −$908MM | $1.6B | 6.8% | $1.3B | 8.5% | $30.3B | $17.10 | 12.6 |
| 2031.Q1 | $11.1B | +3.2% | 26.8% | 13.3% | $2.6B | −$1.1B | $1.5B | 7.1% | $1.1B | 8.4% | $31.4B | $17.39 | 12.4 |
|
| Term. Yr+ | $13.9B | 4.1% | 27.6% | 20.0% | $3.1B | −$1.5B | $1.6B | 8.6% | $17.8B | 8.6% | — | — | — |
Active scenario IV: $222 (+2.8% vs market)